Form 4: CFO Sells Shares to Cover Taxes Under 10b5-1 Plan

Brandi Roberts, Chief Financial Officer of Definium Therapeutics, Inc., sold 3,013 common shares to cover tax withholding obligations as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Brandi Roberts, the Chief Financial Officer of Definium Therapeutics, Inc., reported a transaction on June 25, 2026.
• The transaction involved the sale of 3,013 shares of common stock.
• These shares were sold at a price of $45.03 per share.
• The sale was conducted to satisfy withholding tax obligations related to the settlement of vested restricted stock units.
• This transaction was executed under a Rule 10b5-1 trading plan, which was adopted on May 30, 2025, and is intended to comply with affirmative defense conditions.
• Following this transaction, Roberts beneficially owns 209,487 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sale is a routine event for executive compensation management under a pre-established plan, rather than an indicator of negative company performance or outlook.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating pre-planned and orderly management of equity holdings.
• The sale was specifically to cover tax obligations, a common and expected event for executives receiving stock-based compensation.
• Roberts retains a significant number of shares (209,487) after the transaction, suggesting continued beneficial ownership and alignment with the company.

Negatives

• A sale of company stock by a key executive, even if for tax purposes, can sometimes be perceived negatively by the market.

Risks

• The primary risk is the potential negative market perception of insider selling, regardless of the reason.
• The effectiveness and continued validity of the Rule 10b5-1 plan could be subject to regulatory scrutiny or interpretation.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports a past transaction.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• The sale represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on May 30, 2025.

Industry Context

StockSavvy.ai notes that Form 4 filings reporting sales under Rule 10b5-1 plans are common for executives managing their equity compensation and tax liabilities. These plans are designed to provide a defense against insider trading allegations by establishing a predetermined trading schedule or strategy.

Stakeholder Impact

• Shareholders: May observe the sale, but the Rule 10b5-1 context mitigates concerns about negative insider sentiment.
• Employees: The transaction relates to executive compensation and tax management, with no direct impact on general employee compensation or benefits.
• Management: Demonstrates adherence to established plans for managing equity compensation and tax liabilities.

Next Steps

• Continued monitoring of Brandi Roberts' beneficial ownership and any future transactions.
• Observation of Definium Therapeutics, Inc.'s stock performance and any market reaction to insider transactions.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Tax Withholding, Restricted Stock Units, Definium Therapeutics, DFTX, Brandi Roberts, Chief Financial Officer, Beneficial Ownership